Matches in DBpedia 2014 for { ?s ?p Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers. It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).This drug was developed by Wyeth.It is undergoing numerous clinical trials, including two phase II trials for Non-Hodgkin lymphoma (NHL). A phase III trial for NHL has been terminated due to 'poor enrollment'.. }
Showing items 1 to 2 of
2
with 100 items per page.
- Inotuzumab_ozogamicin abstract "Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers. It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).This drug was developed by Wyeth.It is undergoing numerous clinical trials, including two phase II trials for Non-Hodgkin lymphoma (NHL). A phase III trial for NHL has been terminated due to 'poor enrollment'.".
- Inotuzumab_ozogamicin comment "Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers. It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).This drug was developed by Wyeth.It is undergoing numerous clinical trials, including two phase II trials for Non-Hodgkin lymphoma (NHL). A phase III trial for NHL has been terminated due to 'poor enrollment'.".